Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Viral load testing and CD4 counts

This article was originally published in The Gray Sheet

Executive Summary

"Less costly" AIDS monitoring tools should be developed for "resource-constrained" countries, the Institute of Medicine recommends in July 7 report, "Scaling Up Treatment for the Global AIDS Pandemic." The report urges "development and field evaluation of simple, rapid, inexpensive laboratory tests for diagnosing HIV infections and for monitoring therapeutic responses" as a "high priority" item. IoM singles out the Clinton Foundation's procurement deal with BD for CD4 tests at $8 each. The foundation also is credited with negotiating price drops for Beckman Coulter's CD4 tests and for Roche Diagnostics, Bayer and bioMerieux viral load tests. "The latter reductions make the price up to 80% lower as compared with the currently available lowest-price viral tests," IoM says...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT020561

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel